A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 27 Apr 2023 Planned number of patients changed from 33 to 59.
- 27 Apr 2023 Planned End Date changed from 30 Sep 2025 to 31 Dec 2026.
- 27 Apr 2023 Planned primary completion date changed from 30 Sep 2025 to 31 Dec 2026.